Advertisement

Ovarian Hyperstimulation Syndrome

  • C. De Geyter
Conference paper

Abstract

The ovarian hyperstimulation syndrome is a serious iatrogenic complication of reinforcement of ovarian function by drug administration that becomes clinically manifest only in the luteal phase under the influence of exogenous and endogenous reproductive hormones. In severe ovarian hyperstimulation exudate massively penetrates the extravascular room with ensuing ascites, hydrothorax and general edema. The fluid shift is caused by increased capillary permeability with simultaneous decrease of blood pressure. This shift of fluid components results in a hemoconcentration which may lead to thromboembolic phenomena and acute renal insufficiency becoming threatening to life.

Keywords

Embryo Transfer Luteal Phase Ovarian Hyperstimulation Syndrome Acute Renal Insufficiency Thromboembolic Phenomenon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aboulghar MA, Mansour RT, Serour GI, Amin YM (1990) Ultrasonically guided vaginal aspiration of ascites in the treatment of severe ovarian hyperstimulation syndrome. Fertil Steril 53:933–935PubMedGoogle Scholar
  2. Aboulghar MA, Mansour RT, Serour GI, Sattar MA, Amin YM, Elattar I (1993) Management of severe hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol 81:108–111PubMedGoogle Scholar
  3. Adams J, Poison DW, Abdulwahid N, Morris DV, Franks S, Mason HD, Tucker M, Price J (1995) Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet II:1376–1378Google Scholar
  4. Amit A, Yaron Y, Yovel I, Peyser MR, David MP, Botchan A, Lessing JB (1993) Repeated aspiration of ovarian follicles and early corpus luteum cysts in an in-vitro fertilization programme reduces the risk of ovarian hyperstimulation syndrome in high responders. Hum Reprod 8:1184–1186PubMedGoogle Scholar
  5. Balasch J, Carmona F, Llach J, Arroyo V, Jové I, Vanrell JA (1990) Acute prerenal failure and liver dysfunction in a patient with severe ovarian hyperstimulation syndrome. Hum Reprod 5:348–351PubMedGoogle Scholar
  6. Balasch J, Arroy V, Carmona F, Llach J, Jiménez W, Paré JC, Vanrell JA (1991) Severe ovarian hyperstimulation syndrome: role of peripheral vasodilation. Fertil Steril 56:1077–1083PubMedGoogle Scholar
  7. Blankstein J, Shalev J, Saadon T, Kukia EE, Rabinovici J, Pariente C, Lunenfeld B, Serr DM, Mashiah S (1987) Ovarian hyperstimulation syndrome: prediction by number and size of preovulatory ovarian follicles. Fertil Steril 47:597–601PubMedGoogle Scholar
  8. Borenstein R, Elhalah U, Lunenfeld B, Schwartz ZS (1989) Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 51:791–795PubMedGoogle Scholar
  9. DeGeyter Ch, DeGeyter M, Castro E, Bals-Pratsch M, Hanker JP, Schlegel W, Nieschlag E, Schneider HPG (1993) Predictive parameters for ovarian response to hyperstimulation with exogenous gonadotropins after suppression of gonadotropin secretion of the pituitary using a long-acting GnRH agonist. Eur J Obstet Gynec Reprod Biol 51:139–147CrossRefGoogle Scholar
  10. Emperaire JC, Ruffle A (1991) Triggering ovulation with endogenous luteinizing hormone may prevent the ovarian hyperstimulation syndrome. Hum Reprod 6:506–510PubMedGoogle Scholar
  11. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A (1992) Dopamine treatment for severe hyperstimulation syndrome. Hum Reprod 7:180–183PubMedGoogle Scholar
  12. Friedman CH, Schmidt GE, Chang FE, Kim MH (1984) Severe ovarian hyperstimulation syndrome following follicular aspiration. Am J Obstet Gynecol 150:436–437PubMedGoogle Scholar
  13. Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y, Caspi E (1988) Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. Fertil Steril 50:912–916PubMedGoogle Scholar
  14. Gustafson O, Carlström K, Nylund L (1992) Androstenedione as a predictor of ovarian hyperstimulation syndrome. Hum Reprod 7:918–921PubMedGoogle Scholar
  15. Hammerstein J (1967) Gefahren der ovariellen Überstimulierung bei Anwendung von Clomiphen und Gonadotropinen zur Ovulationsauslösung. Geburtsh Frauenh 12:1125–1251Google Scholar
  16. Haning JR RV, Austin CW, Carlson IH, Kuzma DL, Shapiro SS, Zweibel WJ (1983) Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril 40:31–36PubMedGoogle Scholar
  17. Imoedemhe DAG, Chan RCW, Sigue AB, Pacpaco ELA, Olazo AB (1991) A new approach to the management of patients at risk of ovarian hyperstimulation in an invitro fertilization programme. Hum Reprod 6:1988–1091Google Scholar
  18. Knox GE (1994) Antihistamine blockade of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 118:992–994Google Scholar
  19. Mordel N, Schenker JG (1993) Gonadotrophin-releasing hormone agonist and ovarian hyperstimulation syndrome in assisted reproduction. Hum Reprod 8:2009–2014PubMedGoogle Scholar
  20. Navot D, Margalioth EJ, Laufer N, Birkenfeld A, Relou A, Rosier A, Schenker JG (1987) Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome. Fertil Steril 48:57–61PubMedGoogle Scholar
  21. Navot D, Bergh PA, Laufer N (1992) Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 58:249–261PubMedGoogle Scholar
  22. Salat-Baroux J, Alvarez S, Antoine JM, Cornet D, Tibi Ch, Plachot M, Mandelbaum J (1990) Treatment of hyperstimulation during in-vitro fertilization. Hum Reprod 5:36–39PubMedGoogle Scholar
  23. Scham et al. 1994Google Scholar
  24. Schenker JG, Polishuk WZ (1976) The role of prostaglandins in ovarian hyperstimulation syndrome. Eur J Obstet Gynec Reprod Biol 6:47–52CrossRefGoogle Scholar
  25. Schenker JG, Weinstein D (1978) Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 30:255–268PubMedGoogle Scholar
  26. Schenker JG (1991) Prevention and treatment of ovarian hyperstimulation. Hum Reprod 8:653–659Google Scholar
  27. Smitz J, Camus M, Devroey P, Erard P, Wisanto A, Van Steirteghem AC (1990) Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization. Hum Reprod 5:933–937PubMedGoogle Scholar
  28. Tan SL, Balen A, El Hussein E, Campbell S, Jacobs HS (1992) The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study. Fertil Steril 58:378–383PubMedGoogle Scholar
  29. Wada I, Matson PL, Troup SA, Hughes S, Buck P, Lieberman BA (1992) Outcome of treatment subsequent to the elective cryopreservation of all embryos from women at risk of the ovarian hyperstimulation syndrome. Hum Reprod 7:962–966PubMedGoogle Scholar
  30. Yarali H, Fleige-Zahradka BG, Yuen BH, McComb PF (1993) Tne ascites in the ovarian hyperstimulation syndrome does not originate from the ovary. Fertil Steril 59:657–661PubMedGoogle Scholar
  31. Younis JS, Zeevi D, Rabinovicz R, Laufer N, Schenker JG (1988) Transient liver function test abnormalities in ovarian hyperstimulation syndrome. Fertil Steril 50:176–178PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • C. De Geyter

There are no affiliations available

Personalised recommendations